Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists..., oral small molecules, the Pharvaris team is advancing new alternatives to injected therapies for the prevention...
Lugar:
Newark, NJ | 05/08/2026 17:08:14 PM | Salario: S/. $160000 - 185000 per year | Empresa:
PharvarisPharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists..., oral small molecules, the Pharvaris team is advancing new alternatives to injected therapies for the prevention...
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists..., oral small molecules, the Pharvaris team is advancing new alternatives to injected therapies for the prevention...
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists..., oral small molecules, the Pharvaris team is advancing new alternatives to injected therapies for the prevention...
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists..., oral small molecules, the Pharvaris team is advancing new alternatives to injected therapies for the prevention...
Pharvaris is a late-stage biopharmaceutical company developing novel oral bradykinin B2 receptor antagonists to address... small molecules, the Pharvaris team is creating new alternatives to injected therapies for preventing and treating...
Pharvaris is a late-stage biopharmaceutical company developing novel oral bradykinin B2 receptor antagonists to address... small molecules, the Pharvaris team is creating new alternatives to injected therapies for preventing and treating...
Pharvaris is a late-stage biopharmaceutical company developing novel oral bradykinin B2 receptor antagonists to address... small molecules, the Pharvaris team is creating new alternatives to injected therapies for preventing and treating...
Pharvaris is a late-stage biopharmaceutical company developing novel oral bradykinin B2 receptor antagonists to address... small molecules, the Pharvaris team is creating new alternatives to injected therapies for preventing and treating...